8 unknown. 8 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 8 |
| Phase 1 | 6 | Unknown 6 |
Follow Acute Lymphocytic Leukemia: new trials by email Literature Review of Acute Lymphocytic Leukemia trials Research Report on Acute Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies Drugs and anti-CD19 CAR transduced T cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Guangzhou Medical University | 100 | 2017-06-30 | 2017-06-20 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-10-01 | 2016-10-25 |
| PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma anti-CD19 CAR-NK cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-09-01 | 2016-12-06 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-07-01 | 2016-08-01 |
| PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia PR104 - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Proacta, Incorporated | 50 | 2010-01-01 | 2012-08-31 |
| Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia Liposomal Annamycin - Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Callisto Pharmaceuticals | 34 | 2005-10-01 | 2007-12-21 |
| Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor Tacrolimus and MMF - Multiple Myeloma, Lymphoma | Phase 2 | Unknown | Colorado Blood Cancer Institute | 40 | 2004-03-01 | 2008-02-08 |
| Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. imatinib - Acute Lymphocytic Leukemia | Phase 2 | Unknown | Hospices Civils de Lyon | 30 | 2002-08-01 | 2007-04-27 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Leukemia, Prolymphocytic, B-Cell (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Mantle-Cell (3) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Leukemia (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1)
Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Leukemia, Lymphoid (8) · Lymphatic Diseases (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Leukemia (7) · Chronic Disease (4) · Disease Attributes (4) · Leukemia, B-Cell (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4)
Antigens, CD19 (3) · Sensitivity and Specificity (3) · Immunotherapy, Adoptive (2) · Imatinib Mesylate (1) · Pharmaceutical Preparations (1) · Tacrolimus (1)
PersonGen BioTherapeutics (Suzhou) Co., Ltd. (3) · Callisto Pharmaceuticals (1) · Colorado Blood Cancer Institute (1) · Hospices Civils de Lyon (1) · Proacta, Incorporated (1) · Second Affiliated Hospital of Guangzhou Medical University (1)
China (4) · United States (3) · France (1)
Gary Jacob, PhD (1) · Lin Yang, Ph.D. (1) · Mingjun Wang, MD (1) · Peter A McSweeney, MD (1) · Xin Liu, Ph.D. (1) · Xingbing Wang, Ph.D. (1) · Ying Feng, MD (1)